| Dr Dan Ladd Field, MD | |
|
2865 Sunrise Blvd., Suite 200, Mdstaffers, Rancho Cordova, CA 95742-7204 | |
| (866) 907-8233 | |
| (888) 808-8233 |
| Full Name | Dr Dan Ladd Field |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 2865 Sunrise Blvd., Suite 200, Rancho Cordova, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083792766 | NPI | - | NPPES |
| 00G571500 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G57150 (California) | Primary |
| Entity Name | Med-7 Urgent Care Center Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659475887 PECOS PAC ID: 3971590670 Enrollment ID: O20040426001655 |
News Archive
Ohio University scientists have identified several proteins in mice that might act as biomarkers for growth hormone. The research could be the first step to finding a more reliable way to detect recombinant human growth hormone (rhGH), which some athletes and teenagers use illegally to boost muscle and reduce fat.
Reverse Medical Corporation today announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device (VRD). The BARREL Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms.
Molina Healthcare, Inc. today reported its financial results for the first quarter ended March 31, 2011.
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
› Verified 5 days ago
| Entity Name | Acute Medical Providers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942571146 PECOS PAC ID: 1153589874 Enrollment ID: O20120225000135 |
News Archive
Ohio University scientists have identified several proteins in mice that might act as biomarkers for growth hormone. The research could be the first step to finding a more reliable way to detect recombinant human growth hormone (rhGH), which some athletes and teenagers use illegally to boost muscle and reduce fat.
Reverse Medical Corporation today announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device (VRD). The BARREL Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms.
Molina Healthcare, Inc. today reported its financial results for the first quarter ended March 31, 2011.
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dan Ladd Field, MD 2865 Sunrise Blvd., Suite 200, Mdstaffers, Rancho Cordova, CA 95742-6104 Ph: (866) 907-8233 | Dr Dan Ladd Field, MD 2865 Sunrise Blvd., Suite 200, Mdstaffers, Rancho Cordova, CA 95742-7204 Ph: (866) 907-8233 |
News Archive
Ohio University scientists have identified several proteins in mice that might act as biomarkers for growth hormone. The research could be the first step to finding a more reliable way to detect recombinant human growth hormone (rhGH), which some athletes and teenagers use illegally to boost muscle and reduce fat.
Reverse Medical Corporation today announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device (VRD). The BARREL Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms.
Molina Healthcare, Inc. today reported its financial results for the first quarter ended March 31, 2011.
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
› Verified 5 days ago